# Chemours Co: Form 10-Q for the period ended Sep 30, 2015

- Company: [Chemours Co](/companies/cc.md) (CIK 1627223)
- Form: 10-Q
- Filed: 2015-11-05
- Accepted by EDGAR: Nov 5, 2015, 17:19 ET
- Period: 2015-09-30
- Accession: 0001627223-15-000050
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1627223/000162722315000050/cc-2015930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1627223/000162722315000050/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-07-01 to 2015-09-30 | $1.49bn | us-gaap:Revenues |
| Revenue | 9 months, 2015-01-01 to 2015-09-30 | $4.36bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-07-01 to 2015-09-30 | $1.22bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2015-01-01 to 2015-09-30 | $3.62bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2015-07-01 to 2015-09-30 | $264.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2015-01-01 to 2015-09-30 | $742.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2015-07-01 to 2015-09-30 | $18.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2015-01-01 to 2015-09-30 | $68.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2015-07-01 to 2015-09-30 | $157.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2015-01-01 to 2015-09-30 | $481.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months, 2015-07-01 to 2015-09-30 | $51.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2015-01-01 to 2015-09-30 | $79.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-07-01 to 2015-09-30 | −$78.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-01-01 to 2015-09-30 | −$63.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-07-01 to 2015-09-30 | −$29.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-01-01 to 2015-09-30 | −$4.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-07-01 to 2015-09-30 | −$0.16 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-01-01 to 2015-09-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-07-01 to 2015-09-30 | −$0.16 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-01-01 to 2015-09-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-07-01 to 2015-09-30 | 180,968,049 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-01-01 to 2015-09-30 | 180,968,049 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2015-01-01 to 2015-09-30 | −$120.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2015-01-01 to 2015-09-30 | $392.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2015-01-01 to 2015-09-30 | $100.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2015-09-30 | $215.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-09-30 | $2.48bn | us-gaap:AssetsCurrent |
| Total assets | at 2015-09-30 | $6.45bn | us-gaap:Assets |
| Current liabilities | at 2015-09-30 | $1.50bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-09-30 | $6.36bn | us-gaap:Liabilities |
| Long-term debt | at 2015-09-30 | $3.92bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2015-09-30 | $38.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2015-09-30 | $86.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 57,830 characters.

### Introduction

Management’s discussion and analysis, which we refer to in this filing as “MD&A,” of our results of operations and financial condition is provided as a supplement to the Interim Consolidated Financial Statements and related notes included elsewhere herein to help provide an understanding of our financial condition, changes in financial condition and results of our operations. Our MD&A is based on financial data derived from the financial statements prepared in accordance with the United States (U.S.) generally accepted accounting principles (GAAP) and certain other financial data (Adjusted EBITDA) that is prepared using non-GAAP measures. See Note 20 of Notes to the Interim Consolidated Financial Statements (Unaudited) for a definition of Adjusted EBITDA and a reconciliation of Adjusted EBITDA to net (loss) income.

Chemours management uses Adjusted EBITDA to evaluate the company’s performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business between reporting periods. The company includes this non-GAAP financial measure because management believes it is useful to investors in that it provides for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Chemours’ management believes that the presentation of this non-GAAP financial measure, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the company’s operating performance and underlying prospects. Adjusted EBITDA should not be considered a substitute for net (loss) income.

Unless the context otherwise requires, references herein to “The Chemours Company,” “The Chemours Company, LLC,” “Chemours,” “we,” “us,” “our” and “our company” refer to The Chemours Company and its combined subsidiaries. References herein to “DuPont” refers to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its combined subsidiaries), unless the context otherwise requires. References to “DuPont stockholders” refer to stockholders of DuPont in their capacity as holders of common stock only, unless context otherwise requires.

### Cautionary Statements About Forward-Looking Statements

The discussion and analysis presented below refer to and should be read in conjunction with the financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q (the Interim Consolidated Financial Statements), the audited combined financial statements (the Annual Combined Financial Statements) and related notes, and the unaudited pro forma combined financial statements (the Pro Forma Combined Financial Statements), each in our Information Statement included in our Registration Statement.

This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and in our Information Statement included in our Registration Statement in the Risk Factors discussion. We believe the assumptions underlying the consolidated financial statements are reasonable. However, the consolidated financial statements included herein may not necessarily reflect our results of operations, financial position and cash flows in the future or what they would have been had we been a separate, stand-alone company during the periods presented.

Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours’ control. Some of the important factors that could cause Chemours’ actual results to differ materially from those projected in any such forward-looking statements are:

- Fluctuations in energy and raw material prices;
- Failure to develop and market new products and optimally manage product life cycles;
- Difficulty fulfilling our obligations under our indebtedness;
- Uncertainty regarding the availability of financing to us in the future, including access to our revolving credit facilities, and the terms of such financing;
- Significant litigation and environmental matters;
- Failure to appropriately manage process safety and product stewardship issues;
- Changes in laws and regulations or political conditions;
- Global economic and capital markets conditions, such as inflation, interest and currency exchange rates, and commodity prices, as well as regulatory requirements;
- Business or supply disruptions;
- Security threats, such as acts of sabotage, terrorism or war, weather events and natural disasters;
- Ability to protect, defend and enforce Chemours’ intellectual property rights;
- Increased competition;
- Increasing consolidation of our core customers;
- Changes in relationships with our significant customers and suppliers;
- Significant or unanticipated expenses such as litigation or legal settlement expenses;
- Unanticipated business disruptions;
- Our ability to predict, identify and interpret changes in consumer preference and demand;
- Our ability to realize the expected benefits of the separation;
- Our ability to complete proposed divestitures or acquisitions and our ability to realize the expected benefits of acquisitions if they are completed;
- Our ability to deliver cost savings as anticipated, whether or not on the timelines proposed;
- Our ability to pay or the amount of any dividend; and,
- Disruptions in our information technology networks and systems.

Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. For further discussion of some of the important factors that could cause Chemours’ actual results to differ materially from those projected in any such forward-looking statements, see the Risk Factors discussion in our Information Statement included in our Registration Statement.

The Company assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

### Overview

Chemours is a leading global provider of performance chemicals that are key inputs in products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide, refrigerants, industrial fluoropolymer resins and a portfolio of industrial chemicals including sodium cyanide, sulfuric acid and aniline.

Chemours manages and reports operating results through three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Our position with each of these businesses reflects the strong value proposition we provide to our customers based on our long history of innovation and our reputation within the chemical industry for safety, quality and reliability.

Our business is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours’ operations are primarily located in the U.S., Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, the United Kingdom, France and Sweden.

Chemours’ manufacturing processes consume significant amounts of titanium ore, hydrocarbons and energy which are dependent on oil and natural gas pricing. The cost of these materials varies, reflecting market prices for oil and natural gas and other related inputs. Variations in cost relating to these inputs can be significant, and are described more fully in our risk factors discussion in our Information Statement included in our Registration Statement.

In addition to the dedicated sites described below, the Company operates two production facilities that support both the Fluoroproducts and Chemical Solutions segments for a total of 36 sites.

### Titanium Technologies

Our Titanium Technologies segment is the leading global producer of TiO2, a premium white pigment used to deliver opacity. Titanium Technologies operates in five dedicated production facilities in the U.S., Mexico and Taiwan.

Revenue and earnings performance in Titanium Technologies reflect the cyclical nature of the global TiO2 business. Following the global financial crisis, global economic recovery resulting from the impact of government stimulus resulted in strong customer demand for TiO2 compared to available supply. This drove TiO2 prices higher, ultimately reaching a historical peak in 2012. As global GDP growth fell back to between 2% and 2.5% annual growth and new capacity came online throughout the industry from expansion decisions made in the period of strong demand during the global economic recovery, prices began to decline.

TiO2 pricing tends to move up and down in a cyclical manner depending in large part on global economic conditions. When customer demand is strong, TiO2 price typically increases. A declining global economic cycle softens TiO2 demand, resulting in lower capacity utilization and prices can begin to decline. TiO2 market cycles and swings in supply and demand are principally driven by global economic cycles and the time required to increase TiO2 production capacity.

In the declining phase of the TiO2 cycle, prices can fall to the point where higher cost producers may be selling product at or below production cost. Although Chemours management does not have precise information regarding the prices and costs of other producers, our assessment of current global economic conditions and other factors is that we believe the industry is likely nearing the breakeven point in the TiO2 market cycle. As described, we have unique capabilities which deliver the industry’s best cost position, so we have been able to continue to maintain operating cash flow during the down phase of the cycle.

### Fluoroproducts

Our Fluoroproducts segment is a leading global provider of fluoroproducts, such as refrigerants and industrial fluoropolymer resins. Our Fluoroproducts segment has manufacturing and contract manufacturing in 17 dedicated sites in the U.S., Belgium, France, the Netherlands, Sweden and Brazil.

The Fluoroproducts segment sells products through three principal groups: Fluorochemicals, Industrial Resins and Diversified Technologies. Our Fluorochemicals products include refrigerants, foam expansion agents, propellants and fire extinguishants. Our Industrial Resins products serve a wide range of industrial and end user applications spanning from wearable electronics, to network cables, pipe lining and gaskets, corrosion resistance and thermal stability, among others. Diversified Technologies products also serve a wide range of industrial and end user applications including but not limited to automotive, surface protection, and non-stick adhesion. Fluorochemicals' refrigerant sales fluctuate by season as sales in the first half of the year generally are slightly higher than sales in the second half of the year; however, shifts in the product portfolio in recent quarters have partially offset this impact.

Change in the Fluorochemicals and part of the Fluoropolymers industry is primarily driven by environmental regulatory change. As new regulations are implemented, customers are required to transition to new products and technologies to meet tighter regulatory standards. Our future performance will be driven in part by our ability to successfully manage product line transitions by continuing to meet demand for products that are being phased down, while remaining a leader in the introduction of new, more sustainable, cost-effective and easy-to-implement solutions that allow customers to adopt products to meet new regulatory requirements, and in part by our ability to continue to deliver on productivity.

### Chemical Solutions

Our Chemical Solutions segment is a leading North American provider of industrial and specialty chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries. Chemical Solutions operates in 12 dedicated sites in the U.S. and the United Kingdom.

Chemical Solutions operates in three key market segments of cyanides, sulfur products and performance chemicals. In the cyanides market, we intend to continue our strategy to engage in long-term, multi-year contractual relationships with key customers and invest in initiatives to further improve our uptime and yields. In the sulfur and performance chemicals market segments, our focus will be to reduce overall manufacturing cost and to take actions to improve the profitability levels of underperforming product lines. During the third quarter of 2015, as part of our Transformation Plan, we announced our intention to evaluate strategic alternatives for this segment, excluding the cyanides product lines. As of September 30, 2015, that evaluation is ongoing and is expected to result in a combination of asset sales, site shutdowns and other measures to improve segment profitability.

### Separation from DuPont

On July 1, 2015 (the Distribution Date), DuPont completed the previously announced spin-off of Chemours by distributing Chemours' common stock, on a pro rata basis, to DuPont's stockholders of record as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the Distribution). On the Distribution Date, each holder of DuPont common stock received one share of Chemours' common stock for every five shares of DuPont's common stock held on the Record Date. The spin-off was completed pursuant to a Separation Agreement and several other agreements with DuPont related to the spin-off, including an Employee Matters Agreement, a Tax Matters Agreement, a Transition Services Agreement and an Intellectual Property Cross-License Agreement, each of which was filed with the SEC as an exhibit to our Current Report on Form 8-K on July 1, 2015. These agreements govern the relationship among Chemours and DuPont following the spin-off and provide for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours. For a discussion of each agreement, see the section entitled “Certain Relationships and Related Party Transactions — Agreements with DuPont Related to the Spin-Off” in our Information Statement included in our Registration Statement.

### Recent Developments

### Transformation Plan

During the third quarter of 2015, Chemours announced a plan to transform the company by reducing structural costs, growing market positions, optimizing its portfolio, refocusing investments, and enhancing its organization. Chemours expects the transformation plan will deliver $500 million of Adjusted EBITDA improvement by 2017. Through a combination of higher free cash flow from operations, lower capital spending, and potential proceeds from asset sales, the Company anticipates reducing its leverage (net debt to Adjusted EBITDA) to approximately three times by year-end 2017. Key actions initiated under the Transformation Plan during the quarter included Titanium Technologies plant and production line closures, Fluoroproduct line closures and other cost reduction initiatives. See Note 20 of Notes to the Interim Consolidated Financial Statements (Unaudited) for a reconciliation of Adjusted EBITDA to net (loss) income.

### Titanium Technologies Plant Closures

In August 2015, the Company announced its plan to close its Edge Moor, DE manufacturing site located in the United States. The Edge Moor plant produced titanium dioxide (TiO2) product for use in the paper industry and other applications where demand has steadily declined steadily and has resulted in underused capacity at the plant. In addition, as part of the plan, the Company permanently shut down one underused TiO2 production line at its New Johnsonville, TN plant in the U.S. The Company stopped production at Edge Moor in September 2015 and immediately began decommissioning the plant. The Company expects to complete decommissioning activities in first quarter of 2016 and will begin dismantling thereafter. Dismantling and removal activities are expected to be completed in early 2017.

As a result, for the three months ended September 30, 2015, the Company recorded charges of approximately $126 million, which consist of property, plant and equipment and other asset impairment charges of $114 million and employee separation costs of $12 million. These charges were allocated entirely to the Titanium Technology segment. The Company also expects to incur additional charges of approximately $65 million for decommissioning, dismantling and removal costs from fourth quarter 2015 to early 2017, which will be expensed as incurred. Because the Company is in the early stages of implementing this plan, the amount and timing of the above estimates may differ materially from the amounts provided.

### Chemical Solutions Asset Impairments

During the three months ended September 30, 2015, in connection with the strategic evaluation of the Chemical Solutions operating segment portfolio, we determined that certain Chemical Solutions manufacturing facilities in the United States should be assessed for impairment driven primarily by continued losses experienced by the business. The assessment indicated that the carrying amount of certain long-lived assets in the United States were not recoverable when compared to the expected undiscounted cash flows of business. Based on our assessment of the fair value of the related asset groups, we determined that the carrying value of certain asset groups exceeded its fair value. As a result of the impairment test, a $45 million pre-tax impairment charge was recorded in the Chemical Solutions segment. See Note 12 of Notes to the Interim Consolidated Financial Statements (Unaudited) for further discussion.

In addition, during the quarter ended September 30, 2015, the Company determined that indicators were present in the Sulfur reporting unit which suggested that the fair value of the reporting unit had declined below the carrying value, primarily driven by lower than forecasted revenue and profitability levels for 2015 and future periods. The interim goodwill impairment analysis performed in the third quarter of 2015 resulted in a goodwill impairment of $25 million for the three and nine months ended September 30, 2015. See Note 13 of Notes to the Interim Consolidated Financial Statements (Unaudited) for further discussion.

### Recent Accounting Pronouncements

See Note 3 to the Interim Consolidated Financial Statements (Unaudited) for a discussion of recent accounting pronouncements.

### Our Third Quarter 2015 Results and Business Highlights

Net sales for the three months ended September 30, 2015 were $1.5 billion, a decrease of 9% from $1.6 billion for the three months ended September 30, 2014. We recognized a net loss of $29 million for the three months ended September 30, 2015, compared with net income of $108 million for the same period in 2014. Our results for the quarter reflect improvement from cost reductions and strong Fluoroproducts performance, offset by a weak TiO2 environment and $184 million of employee separation costs and related asset charges. Adjusted EBITDA was $169 million and $235 million for the three months ended September 30, 2015 and 2014, respectively. A reconciliation of Adjusted EBITDA to net (loss) income for the three and nine months ended September 30, 2015 and 2014 is included in Note 20 to the Interim Consolidated Financial Statements (Unaudited) .

### Results of Operations

*(Dollars in millions)*

|  | Three months ended September 30, 2015 | 2014 | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,486 | $1,632 | $4,357 | $4,883 |
| Cost of goods sold | 1,222 | 1,273 | 3,615 | 3,824 |
| Gross profit | 264 | 359 | 742 | 1,059 |
| Selling, general and administrative expense | 157 | 176 | 481 | 532 |
| Research and development expense | 18 | 33 | 68 | 110 |
| Employee separation and asset related charges, net | 184 | — | 245 | 21 |
| Goodwill impairment | 25 | — | 25 | — |
| Total expenses | 384 | 209 | 819 | 663 |
| Equity in earnings of affiliates | 7 | 6 | 18 | 18 |
| Interest expense | (51) | — | (79) | — |
| Other income, net | 57 | (13) | 71 | 16 |
| **(Loss) income before income taxes** | (107) | 143 | (67) | 430 |
| (Benefit from) provision for income taxes | (78) | 35 | (63) | 108 |
| **Net (loss) income** | (29) | 108 | (4) | 322 |
| Less: Net income attributable to noncontrolling interests | — | 1 | — | 1 |
| **Net (loss) income attributable to Chemours** | $(29) | $107 | $(4) | $321 |

### Net Sales

Net sales in the third quarter of 2015 were $1.5 billion, a decrease of approximately 9% compared to $1.6 billion in the third quarter of 2014, which was primarily due to continued pricing pressures in the TiO2 market and unfavorable impact of foreign currencies against the U.S. dollar, which was offset by volume growth across all segments.

The table below shows the impact of price, currency, volume and portfolio on net sales for the three months ended September 30, 2015 compared with 2014 :

*(Dollars in millions)*

|  | 2015 Net Sales | Percentage Change vs 2014 | Percentage change due to: Local Price | Currency Effect | Volume | Portfolio/Other |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Worldwide | $1,486 | (9)% | (5)% | (7)% | 4% | (1)% |

Net sales for the nine months ended September 30, 2015 were $4.4 billion, a decrease of approximately 11% compared to $4.9 billion in the nine months ended September 30, 2014, which was primarily due to continued pressure on TiO2 prices and the negative impact of foreign currency, offset by volume growth in Fluoroproducts and our Chemical Solutions portfolio.

The table below shows the impact of price, currency, volume and portfolio on net sales for the nine months ended September 30, 2015 compared with 2014:

*(Dollars in millions)*

|  | 2015 Net Sales | Percentage Change vs 2014 | Percentage change due to: Local Price | Currency Effect | Volume | Portfolio/Other |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Worldwide | $4,357 | (11)% | (5)% | (4)% | (1)% | (1)% |

### Cost of goods sold

Cost of goods sold (COGS) decreased 4% during the third quarter of 2015 and decreased 5% in comparison with the nine months ended September 30, 2014; however, COGS as a percentage of net sales increased over the same periods. This increase is primarily driven by raw material costs in our Titanium Technologies segment.

The following table shows COGS as a percent of net sales.

*(Dollars in millions)*

|  | Three months ended September 30, 2015 | 2014 | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,486 | $1,632 | $4,357 | $4,883 |
| COGS | 1,222 | 1,273 | 3,615 | 3,824 |
| COGS as a percent of net sales | 82% | 78% | 83% | 78% |

### Selling, general and administrative expense

Selling, general and administrative expense decreased 11% to $157 million for the three months ended September 30, 2015. For the nine months ended September 30, 2015, selling, general and administrative expense decreased to $481 million. For both periods, the change was primarily driven by lower third quarter functional support costs and spend, partially offset by higher stock-based compensation charges related to conversion awards.

Selling, general and administrative expense as a percent of net sales is shown in the following table.

*(Dollars in millions)*

|  | Three months ended September 30, 2015 | 2014 | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,486 | $1,632 | $4,357 | $4,883 |
| Selling, general and administrative expense | 157 | 176 | 481 | 532 |
| Selling, general and administrative expense as a percent of net sales | 11% | 11% | 11% | 11% |

37

### Research and development expense

Research and development expense decreased by $15 million and $42 million for the three and nine months ended September 30, 2015, respectively, in comparison with the same periods in 2014, primarily due to decreased spending across all segments. Reductions in research and development spend are primarily driven by decisions to either delay or terminate projects following our separation.

Research and development expense as a percent of net sales is shown in the following table.

*(Dollars in millions)*

|  | Three months ended September 30, 2015 | 2014 | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Net sales | $1,486 | $1,632 | $4,357 | $4,883 |
| Research and development expense | 18 | 33 | 68 | 110 |
| Research and development expense as a percent of net sales | 1% | 2% | 2% | 2% |

### Interest expense

We incurred interest expense of $51 million and $79 million for three and nine months ended September 30, 2015 related to our financing transactions. There was no comparable expense in 2014 for either period. Refer to Note 15 to the Interim Consolidated Financial Statements (Unaudited) for additional information related to our debt instruments.

### Employee separation and asset-related charges, net

For the three and nine months ended September 30, 2015, we recorded pre-tax charges of approximately $184 million and $245 million, respectively, for employee separation and other asset-related charges in connection with several actions. This cost includes $126 million related to our capacity optimization in our Titanium Technology segment, including the closing of our Edge Moor production facility and $10 million of Fluoroproducts restructuring activities. In addition, in connection with the evaluation of strategic alternatives for our Chemical Solutions reportable segment, we recognized a $45 million fixed asset impairment as well as a $25 million impairment of goodwill in this reportable segment.

See Notes 6, 12 and 13 to the Interim Consolidated Financial Statements (Unaudited) for additional details related to the nature and timing of these items.

### Other income, net

For the three and nine months ended September 30, 2015, other income, net increased by $70 million and by $55 million, respectively. In both periods, the increase is attributable to foreign exchange gains recognized in 2015 compared to foreign exchange losses recognized in the prior year.

### Provision for income taxes

For the three months ended September 30, 2015, Chemours recorded a tax benefit of $78 million with an effective income tax rate of approximately 73%. For the three months ended September 30, 2014, Chemours recorded a tax provision of $35 million with an effective tax rate of approximately 24%. The $113 million decrease in the tax provision was due primarily to tax benefits recognized from the restructuring and asset impairment charges in the U.S. recorded in the third quarter of 2015, partially offset by earnings in foreign jurisdictions.

For the nine months ended September 30, 2015, Chemours recorded a tax benefit of $63 million with an effective income tax rate of approximately 94%. For the nine months ended September 30, 2014, Chemours recorded a tax provision of $108 million with an effective income tax rate of approximately 25%. The $171 million decrease in the tax provision was due primarily to tax benefits recognized from the restructuring and asset impairment charges in the U.S. recorded in the third quarter of 2015, partially offset by earnings in foreign jurisdictions.

### Segment Reviews

In general, the accounting policies of the segments are the same as those described in Note 3 to the Annual Combined Financial Statements in our Information Statement included in our Registration Statement, except for segment adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA). Adjusted EBITDA is defined as income (loss) before income taxes excluding the following:

- interest expense, depreciation and amortization,
- non-operating pension and other postretirement employee benefit costs,
- exchange gains (losses),
- employee separation, asset-related charges and other charges, net,
- asset impairments,
- gains (losses) on sale of business or assets, and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

The tables presented below reflect the reclassification of certain corporate costs, certain legal and environmental expenses that are not aligned with our reportable segments, and foreign exchange gains and losses from our reportable segments into Corporate and Other. All periods presented reflect the current definition of Adjusted EBITDA.

A reconciliation of Adjusted EBITDA to net (loss) income for the three and nine months ended September 30, 2015 and 2014 is included in Note 20 to the Interim Consolidated Financial Statements (Unaudited) .

### Titanium Technologies

*(Dollars in millions)*

|  | Three months ended September 30, 2015 | 2014 | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Segment Net Sales | $616 | $754 | $1,803 | $2,249 |
| Adjusted EBITDA | 78 | 189 | 262 | 563 |
| Adjusted EBITDA Margin | 13% | 25% | 15% | 25% |

| Change in segment net sales from prior period | Three Months Ended September 30, 2015 | Nine Months Ended September 30, 2015 |
| --- | ---: | ---: |
| Price | (13)% | (11)% |
| Volume | 2% | (4)% |
| Currency | (7)% | (5)% |
| Portfolio / Other | —% | —% |
| Total Change | (18)% | (20)% |

### Titanium Technology Segment Results

***Segment Net Sales:*** Net sales decreased by 18% in the quarter ended September 30, 2015, compared with the same period in 2014, due primarily to lower selling prices and the continued negative effect of foreign currency, notably the Brazilian real and Japanese yen, while slightly higher volume partially offsets these declines. Low industry utilization and weak demand continue to put downward pressure on pricing in all regions. For the nine months ended September 30, 2015 and 2014, net sales were $1,803 million and $2,249 million respectively, which was a decrease of $446 million.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA decreased during both the three and nine months ended ended September 30, 2015 in comparison with same periods in 2014. Adjusted EBITDA margin also decreased during both the three and nine months ended ended September 30, 2015 in comparison with same periods in 2014. Both decreases were primarily driven by lower sales and margin due to pricing pressures and the effects of foreign currency, partially offset by recent cost reduction efforts.

### Fluoroproducts

*(Dollars in millions)*

|  | Three months ended September 30, 2015 | 2014 | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Segment Net Sales | $575 | $572 | $1,715 | $1,752 |
| Adjusted EBITDA | 89 | 70 | 218 | 209 |
| Adjusted EBITDA Margin | 15% | 12% | 13% | 12% |

| Change in segment net sales from prior period | Three Months Ended September 30, 2015 | Nine Months Ended September 30, 2015 |
| --- | ---: | ---: |
| Price | 4% | 2% |
| Volume | 6% | 2% |
| Currency | (6)% | (4)% |
| Portfolio / Other | (3)% | (2)% |
| Total Change | 1% | (2)% |

### Fluoroproducts Segment Results

***Segment Net Sales:*** Net sales increased by 1% and decreased by 2% for the three and nine months ended September 30, 2015, respectively, compared with the same period in 2014. Both periods demonstrated favorable product mix with strong Opteon refrigerant adoption driving price and volume growth over the prior year. Net sales were unfavorably impacted by foreign currency effects, primarily related to the Brazilian real, Euro and Japanese yen, and weaker demand for fluoropolymer products.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA increased during both the three and nine months ended September 30, 2015 in comparison with same periods in 2014. Adjusted EBITDA margin increased during the three months ended September 30, 2015 and the nine months ended September 30, 2015 in comparison with same periods in 2014. Both changes were primarily due to product mix, normalized plant operations and cost reduction efforts in the third quarter.

***Fluoroproducts Restructuring:*** During the third quarter of 2015, in connection with the Company’s transformation plan announced in August 2015 and to improve the profitability of the Fluoroproducts segment, management approved the shutdown of certain production lines of the Fluoroproducts segment’s manufacturing facilities in the United States due to high fixed costs and/or declining demand for certain products that negatively impacted the segment’s profitability. As a result, the Company recorded restructuring charges of approximately $10 million, which consist of accelerated depreciation on property, plant and equipment of $8 million and employee separation costs of $2 million.

### Chemical Solutions

*(Dollars in millions)*

|  | Three months ended September 30, 2015 | 2014 | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Segment Net Sales | $295 | $306 | $839 | $882 |
| Adjusted EBITDA | 7 | 9 | 12 | 16 |
| Adjusted EBITDA Margin | 2% | 3% | 1% | 2% |

| Change in segment net sales from prior period | Three Months Ended September 30, 2015 | Nine Months Ended September 30, 2015 |
| --- | ---: | ---: |
| Price | (4)% | (4)% |
| Volume | 4% | 2% |
| Currency | (4)% | (3)% |
| Portfolio / Other | —% | —% |
| Total Change | (4)% | (5)% |

40

***Segment Net Sales:*** Net sales decreased by 4% and 5% in the three and nine months ended September 30, 2015 respectively, compared with the same periods in 2014, primarily due to strong Cyanide and Sulfur volumes, offset by mix of products sold and the negative impact of foreign currency.

***Adjusted EBITDA and Adjusted EBITDA margin:*** Adjusted EBITDA decreased during both the three and nine months ended September 30, 2015 in comparison with same periods in 2014, while Adjusted EBITDA margin remained flat. The slight decrease in Adjusted EBITDA is driven primarily by lower sales and margins, including foreign currency impacts, higher warehousing costs and an unplanned outage in the third quarter.

### Liquidity & Capital Resources

Prior to our spin-off on July 1, 2015, transfers of cash to and from DuPont’s cash management system have been reflected in DuPont Company Net Investment in the historical Consolidated Balance Sheets, Statements of Cash Flows and Statements of Changes in DuPont Company Net Investment. DuPont funded our cash needs through the date of the separation. Chemours has a historical pattern of seasonality, with working capital use of cash in the first half of the year, and a working capital source of cash in the second half of the year.

Chemours anticipates that its primary source of liquidity will be cash generated from operations, available cash and borrowings under the debt financing arrangements as described below. We believe these sources are sufficient to fund our planned operations, and to meet our interest, dividend and contractual obligations. Our financial policy seeks to deleverage by using free cash flow to repay outstanding borrowings, selectively invest for growth to enhance our portfolio and financing of strategic capital investments, and return cash to shareholders.

While we were a wholly-owned subsidiary of DuPont, our Board of Directors, consisting of DuPont employees, declared a dividend of an aggregate amount of $100 million for the third quarter of 2015, which was paid on September 11, 2015 to our stockholders of record as of August 3, 2015. On September 1, 2015, our independent Board of Directors declared a dividend of $0.03 per share to be paid on December 14, 2015 to our stockholders of record on November 13, 2015.

During the third quarter of 2015, Chemours recorded a payable to DuPont in accounts payable in our Interim Consolidated Balance Sheets which represents the amount of cash at spin-off in excess of the target amount pursuant to the Separation Agreement. We expect to pay $49 million by December 31, 2015. Additionally. the companies are still finalizing the reconciliation of working capital and other accounts and the net amount due to/from DuPont will be settled in accordance with the Separation Agreement.

### Near Term Liquidity

Over the next 12 months, Chemours is required to make significant payments of interest and dividends. We expect to fund these payments through cash generated from operations, available cash and borrowings under the revolving credit facility. We anticipate that our operations and debt financing arrangements will provide sufficient liquidity over the next 12 months.

### Cash Flow

The following table sets forth a summary of the net cash provided by (used for) operating, investing and financing activities.

*(Dollars in millions)*

|  | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: |
| Cash (used for) provided by operating activities | $(120) | $13 |
| Cash used for investing activities | (355) | (377) |
| Cash provided by financing activities | 695 | 364 |

#### Cash Used for Operating Activities

Cash provided by operating activities decreased by $133 million for the nine months ended September 30, 2015 compared to the same period in 2014 due to lower earnings and increased working capital accounts over the prior year.

#### Cash Used for Investing Activities

Cash used for investing activities decreased $22 million for the nine months ended September 30, 2015 compared to the same period in 2014, primarily as a result of a $12 million decrease in capital expenditures and a $61 million increase in gains realized on foreign exchange contract settlements. The decrease is partially offset by a $32 million increase in investments made in affiliates and a $19 million decrease in proceeds from the sale of assets.

Capital expenditures relating to our Altamira expansion were $28 million and $108 million for the three and nine months ended September 30, 2015, respectively, and $75 million and $167 million for the three and nine months ended September 30, 2014, respectively.

#### Cash Provided by Financing Activities

Through June 30, 2015, DuPont managed Chemours’ cash and financing arrangements and all excess cash generated through earnings was deemed remitted to DuPont and all sources of cash were deemed funded by DuPont. See Note 4 to the Interim Consolidated Financial Statements (Unaudited) for additional information. Prior to the spin-off on July 1, 2015, Chemours remitted approximately $3.4 billion to DuPont in the form of a dividend, using cash received from issuance of debt. Cash provided by financing activities increased $331 million for the nine months ended September 30, 2015 compared to the same period in 2014, primarily from the proceeds of our financing transactions in the prior quarter, offset by net transfers to DuPont prior to separation.

### Current Assets

*(Dollars in millions)*

|  | September 30 2015 | December 31, 2014 |
| --- | ---: | ---: |
| Cash | $215 | $— |
| Accounts and notes receivable - trade, net | 1,102 | 846 |
| Inventories | 993 | 1,052 |
| Prepaid expenses and other | 120 | 43 |
| Deferred income taxes | 51 | 21 |
| Total current assets | $2,481 | $1,962 |

As of December 31, 2014, Chemours participated in DuPont’s centralized cash management and financing programs. Disbursements were made through centralized accounts payable systems which are operated by DuPont. Cash receipts were transferred to centralized accounts, also maintained by DuPont. As such, we did not reflect a cash balance in our financial statements prior to separation. Accounts and notes receivable - trade, net at September 30, 2015 increased $256 million compared to December 31, 2014 primarily due to timing of collections of trade accounts receivable. Prepaid expenses increased $77 million primarily caused by additional prepaid income taxes.

### Current Liabilities

*(Dollars in millions)*

|  | September 30 2015 | December 31, 2014 |
| --- | ---: | ---: |
| Accounts payable | $1,009 | $1,046 |
| Current portion of long-term debt | 38 | — |
| Deferred income taxes | 14 | 9 |
| Other accrued liabilities | 444 | 352 |
| Total current liabilities | $1,505 | $1,407 |

Accounts payable decreased compared to December 31, 2014 due to timing of payments to vendors and cost reduction initiatives, which was offset by a net payable to DuPont which represents the estimated cash and working capital settlement per the Separation Agreement. Current portion of long-term debt primarily reflects our financing transactions completed in May 2015. We had no comparable financing transactions in 2014. Other accrued liabilities increased due to employee separation accruals related to 2015 actions and accrued interest on debt issued in 2015.

### Financing Transactions

On May 12, 2015, Chemours entered into certain financing transactions in connection with the Distribution and in recognition of the assets contributed to it by DuPont in anticipation of the separation. The proceeds from the financing transactions were used to fund a cash distribution to DuPont of $3.4 billion and a distribution in kind of Notes with an aggregate principal amount of $507 million. See Note 15 to the Interim Consolidated Financial Statements (Unaudited) for further discussion of these transactions.

The credit agreement provides for a seven-year senior secured term loan (the Term Loan Facility) in a principal amount of $1.5 billion repayable in equal quarterly installments at a rate of one percent of the original principal amount per year, with the balance payable on the final maturity date. The Term Loan Facility was issued with a $7 original issue discount and bears variable interest rate subject to a floor of 3.75%. The proceeds from the Term Loan Facility were used to fund a portion of the distribution to DuPont, along with related fees and expenses.

The credit agreement provides for a five-year $1.0 billion senior secured revolving credit facility (Revolving Credit Facility). The proceeds of any loans made under the Revolving Credit Facility can be used to finance capital expenditures, acquisitions, working capital needs and for other general corporate purposes. Availability under the Revolving Credit Facility is subject to certain limitations and at September 30, 2015, the facility was undrawn with a borrowing availability of approximately $753 million. We had $129 million letters of credit issued and outstanding under this facility at September 30, 2015.

### Debt Covenants

Chemours is subject to certain debt covenants that, among other things, limit Chemours and certain of Chemours’ subsidiaries to incur indebtedness, pay dividends or make other distributions, prepay, redeem or repurchase certain debt, make loans and investments, sell assets, incur liens, enter into transactions with affiliates and consolidate or merge. These covenants are subject to a number of exceptions and qualifications set forth in the respective agreements. Additionally, under the terms of the credit agreement, Chemours is subject to a maximum consolidated net leverage ratio (calculated by dividing total net debt by EBITDA, both as defined by the credit agreement) of 5.75 to 1.00 until December 31, 2015, and a minimum consolidated interest coverage ratio (calculated by dividing EBITDA by interest expense, both as defined by the credit agreement) of 3.00 to 1.00. The maximum consolidated net leverage ratio decreases quarterly in 2016 to 5.00 to 1.00 by December 31, 2016. The Senior secured credit facilities and the Notes contain events of default customary for these types of financings, including cross default and cross acceleration provisions to material indebtedness of Chemours.

During the third quarter of 2015, Chemours and its Revolving Credit Facility lenders agreed to amend certain provisions of the credit agreement that relate to the Revolving Credit Facility, strengthening Chemours' financial position by providing enhanced liquidity to implement the Transformation Plan. The amendment modified the consolidated EBITDA definition in the covenant calculation to include pro forma benefits of announced cost reduction initiatives.

Chemours is in compliance with its debt covenants as of September 30, 2015.

### Supplier Financing

Chemours has entered into a global paying services agreement with a financial institution. Under this agreement, the financial institution acts as the paying agent for Chemours with respect to accounts payable due to our suppliers who elect to participate in the program. The agreement allows our suppliers to sell their receivables to the financial institution at the discretion of both parties on terms that are negotiated between them. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers' decisions to sell their receivables under this program. At September 30, 2015, this program provided capacity to Chemours' suppliers of approximately $200 million.

### Capital Expenditures

Our operations are capital intensive, requiring ongoing investment to upgrade or enhance existing operations and to meet environmental and operational regulations. Our capital requirements have consisted, and are expected to continue to consist, primarily of:

- ongoing capital expenditures, such as those required to maintain equipment reliability, the integrity and safety of our manufacturing sites and to comply with environmental regulations;
- investments in our existing facilities to help support introduction of new products and de-bottleneck to expand capacity and grow our business; and
- investment in projects to reduce future operating costs and enhance productivity.

The following table summarizes ongoing and expansion capital expenditures (which includes environmental capital expenditures), as well as expenditures related to our separation from DuPont, for the three and nine month periods ended September 30, 2015 and 2014:

*(Dollars in millions)*

|  | Three months ended September 30, 2015 | 2014 | Nine months ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Capital expenditures - ongoing and expansion | $101 | $173 | $329 | $404 |
| Capital expenditures - separation | 4 | — | 63 | — |
| Capital Expenditures | $105 | $173 | $392 | $404 |

Capital expenditures as a percentage of our net sales were 7% and 11% for the three months ended September 30, 2015 and 2014, respectively, and 9% and 8% for the nine months ended September 30, 2015 and 2014, respectively. The decrease during the third quarter was due to lower spending in 2015 as we finish the expansion of our Altamira production facility, as well as lower spending on information technology compared with 2014.

For the full year 2015, we expect our capital expenditures, excluding separation-related spending, to be about approximately $400 to $450 million and then decline in 2016 and 2017 as we finish the expansion of our Altamira, Mexico production facility. Once our Altamira and cyanide expansion projects are completed, we anticipate that capital spending will return to more normalized spending of about $350 million per year in total for maintenance and growth in 2017. For further detail related to our environmental capital expenditures, please see the Environmental Matters section of this MD&A.

### Contractual Obligations

Chemours' contractual obligations at September 30, 2015 did not significantly change from its contractual obligations previously disclosed at June 30, 2015 and December 31, 2014.

### Off Balance Sheet Arrangements

Information with respect to Chemours's guarantees is included in Note 16 to the Interim Consolidated Financial Statements (Unaudited) and in Note 17 to the Annual Combined Financial Statements in our Information Statement included in our Registration Statement. Historically, Chemours has not made significant payments to satisfy guarantee obligations; however, Chemours believes it has the financial resources to satisfy these guarantees in the event required.

### Critical Accounting Policies and Estimates

Chemours’ significant accounting policies are described in Note 3 to the Interim Consolidated Financial Statements (Unaudited) included herein and Note 3 to the Annual Combined Financial Statements in our Information Statement included in our Registration Statement.

### Environmental Matters

#### Environmental Expenses

Environmental expenses charged to current operations include environmental operating costs and the increase in the remediation accrual, if any, during the period reported. As a result of its operations, Chemours incurs costs for pollution abatement activities including waste collection and disposal, installation and maintenance of air pollution controls and wastewater treatment, emissions testing and monitoring and obtaining permits. Chemours also incurs costs for environmental-related research and development activities including environmental field and treatment studies as well as toxicity and degradation testing to evaluate the environmental impact of products and raw materials. Management expects that such expenses in 2015 will be comparable to 2014 and, therefore, does not believe that year over year changes, if any, in environmental expenses charged to current operations will have a material impact on Chemours’ financial position, liquidity or results of operations.

#### Remediation Accrual

Annual expenditures in the near future are not expected to vary significantly from the range of such expenditures incurred during the past few years. Longer term, expenditures are subject to considerable uncertainty and may fluctuate significantly. There have been no significant changes to the remediation accrual at September 30, 2015 from December 31, 2014.

Chemours is also subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by

Chemours or other parties. Chemours accrues for environmental remediation activities consistent with the policy as described in Note 3 to the Annual Combined Financial Statements. Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), the Resource Conservation and Recovery Act (RCRA) and similar state and global laws. These laws require certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

As of September 30, 2015, Chemours, through DuPont, has been notified of potential liability under the CERCLA or similar state laws at about 174 sites around the U.S., including approximately 22 sites for which Chemours does not believe it has liability based on current information. Active remediation is under way at approximately 56 of these sites. In addition, at September 30, 2015, liability at approximately 64 sites, has been resolved either by completing remedial actions with other Potentially Responsible Parties (PRPs) or participating in "de minimis buyouts" with other PRPs whose waste, like Chemours’, represented only a small fraction of the total waste present at a site. The Company received notice of potential liability at two new sites through September 30, 2015. During 2014, Chemours received notice of three new sites.

At September 30, 2015, the Interim Consolidated Balance Sheet included a liability of $300 million relating to these matters which, in management’s opinion, is appropriate based on existing facts and circumstances. The average time-frame over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15 to 20 years. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other potentially responsible parties. In addition, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular there may be considerable variability between the remediation activities that are currently being undertaken or planned, as reflected in the liability recorded at September 30, 2015, and the ultimate actions that could be required.

Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $630 million above the amount accrued at September 30, 2015. Except for Pompton Lakes, which is discussed further below, based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the financial position, liquidity or results of operations of Chemours.

#### Pompton Lakes

The environmental remediation accrual is $88 million at September 30, 2015 related to activities at Chemours’ site in Pompton Lakes, New Jersey. Management believes that it is reasonably possible that remediation activities at this site could range up to $119 million, including previously accrued amounts. This could have a material impact on the liquidity of Chemours in the period recognized. However, management does not believe this would have a material adverse effect on Chemours’ combined financial position, liquidity or results of operations. During the twentieth century, blasting caps, fuses and related materials were manufactured at Pompton Lakes. Operating activities at the site ceased in the mid 1990’s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds.

Under the authority of the Environmental Protection Agency (EPA) and the New Jersey Department of Environmental Protection, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is ongoing and Chemours, through DuPont, has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site's RCRA permit that requires Chemours to dredge mercury contamination from a 36 acre area of the lake and remove sediment from 2 other areas of the lake near the shoreline. Chemours expects to spend about $50 million over the next two to three years, which is included in the remediation accrual at September 30, 2015, in connection with remediation activities at Pompton Lakes, including activities related to the EPA’s proposed plan. The Company expects these activities to begin sometime on or after mid-2016.

#### Environmental Capital Expenditures

As of December 31, 2014, Chemours spent approximately $40 million on environmental capital projects either required by law or necessary to meet Chemours’ internal environmental goals. Chemours currently estimates expenditures for environmental-related capital projects to be approximately $40 million in 2015, which is included in our estimate of overall capital expenditures discussed in the Liquidity and Capital Resources section of this MD&A. In the U.S., additional capital expenditures are expected to be required over the next decade for treatment, storage and disposal facilities for solid and hazardous waste and for compliance with the Clean Air Act (CAA). Until all CAA regulatory requirements are established and known, considerable uncertainty will remain regarding estimates for future capital expenditures. However, management does not believe that the costs to comply with these requirements will have a material impact on the financial position or liquidity of Chemours.

### PFOA

See discussion under “PFOA” in Note 16 to the Interim Consolidated Financial Statements (Unaudited).

## Market risk

As filed, 6,241 characters.

### Derivatives and Other Hedging Instruments

Fluctuations in the value of the U.S. dollar compared to foreign currencies may impact Chemours' earnings. Through December 2014, Chemours participated in DuPont's foreign currency hedging program to reduce earnings volatility associated with remeasurement of foreign currency denominated net monetary assets. DuPont formally documented the hedge relationships, including identification of the hedging instruments and hedged items, the risk management objectives and strategies for undertaking the hedge transactions, and the methodologies used to assess effectiveness and measure ineffectiveness. Realized gains and losses on derivative instruments of DuPont were allocated by DuPont to Chemours based on projected exposure. Chemours recognized its allocable share of the gains and losses on DuPont's derivative financial instruments in earnings when the forecasted purchases occurred for natural gas hedges and when the forecasted sales occurred for foreign currency hedges.

As disclosed in the Annual Combined Financial Statements in our Information Statement included in our Registration Statement, the impact of Chemours' participation in the foreign currency hedging program was gains of $4 million in 2014. In relation to the parent sponsored program, Chemours was less than five percent of the program participation. Therefore, a ten percent change in rates on the parent sponsored program would have had an immaterial impact on cash flows and net income of Chemours for the year ended December 31, 2014.

Beginning in 2015, Chemours began entering into foreign currency forward contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from translating net monetary assets that Chemours holds which are denominated in non-functional currencies. These derivatives are stand-alone and have not been designated as a hedge. The derivative assets and liabilities are reported on a gross basis in the Interim Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized within other income in the Interim Consolidated Statements of Operations (Unaudited). Chemours does not hold or issue financial instruments for speculative or trading purposes.

In July 2015, Chemours designated its €360 million Euro notes as a hedge of its net investments in certain of its international subsidiaries that use the Euro as functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the Euro with respect to the U.S. dollar. Chemours used the spot method to measure the effectiveness of the net investment hedge. Under this method, for each reporting period, the change in the carrying value of the Euro notes due to remeasurement of the effective portion is reported in accumulated other comprehensive loss in the Interim Consolidated Balance Sheet and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income, net in the Interim Consolidated Statements of Operations. Chemours evaluates the effectiveness of its net investment hedge at the beginning of every quarter. See Note 15 to the Interim Consolidated Financial Statements (Unaudited) for further information regarding our debt.

### Sensitivity Analysis

The following table illustrate the fair values of outstanding derivative contacts at September 30, 2015 and the effect on fair values of a hypothetical adverse change in the market prices or rates that existed at September 30, 2015. Chemours did not hold any derivative contacts at December 31, 2014. Foreign currency sensitivities are based on a ten percent change in market rates.

*(Dollars in millions)*

|  | September 30, 2015 Fair Value Asset | Fair Value Sensitivity |
| --- | ---: | ---: |
| Foreign currency forward contracts | $5 | $(102) |

Chemours' risk management programs and the underlying exposure are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by change in the value of the underlying exposure. See Note 17 to the Interim Consolidated Financial Statements (Unaudited) for further information.

### Concentration of Credit Risk

Chemours' sales are not materially dependent on any single customer. As of September 30, 2015 and December 31, 2014, no one individual customer balance represented more than five percent of Chemours' total outstanding receivables balance. Credit risk associated with Chemours' receivables balance is representative of the geographic, industry and customer diversity associated with

Chemours' global businesses. As a result of our customer base being widely dispersed, we do not believe our exposure to credit-related losses related to our business as of September 30, 2015 and December 31, 2014 was material.

Chemours also maintains strong credit controls in evaluating and granting customer credit. As a result, it may require that customers provide some type of financial guarantee in certain circumstances. Length of terms for customer credit varies by industry and region.

### Commodities Risk

A portion of our products and raw materials are commodities whose prices fluctuate as market supply and demand fundamentals change. Accordingly, product margins and the level of our profitability tend to fluctuate with the changes in the business cycle. Chemours tries to protect against such instability through various business strategies. These include provisions in sales contracts allowing us to pass on higher raw material costs through timely price increases and formula price contracts to transfer or share commodity price risk. Chemours did not have any commodity derivative instruments in place as of September 30, 2015 or December 31, 2014.

### Additional Information

See Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in the Management's Discussion and Analysis section of our Information Statement included in our Registration Statement for information on the company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

## Controls and procedures

As filed, 1,452 characters.

a) Evaluation of Disclosure Controls and Procedures

The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of September 30, 2015, the company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective at the reasonable assurance level described above.

b) Changes in Internal Control over Financial Reporting

There has been no change in the Company's internal control over financial reporting that occurred during the quarter ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

## Risk factors

As filed, 177 characters.

There have been no material changes in the company's risk factors discussed in Part I, Item 1A, Risk Factors in our Information Statement included in our Registration Statement.

Filed Nov 5, 2015.
Source: SEC EDGAR, the filing index for accession 0001627223-15-000050. Last ingested by Listed: Nov 5, 2026, 19:57 ET. No prices; not investment advice.
